Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF – Get Free Report) saw unusually-high trading volume on Tuesday . 500 shares changed hands during trading, an increase of 39% from the previous session’s volume of 361 shares.The stock last traded at $80.00 and had previously closed at $81.00.
Wall Street Analyst Weigh In
DSRLF has been the subject of a number of analyst reports. UBS Group lowered shares of DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. Zacks Research upgraded shares of DiaSorin to a “hold” rating in a research note on Tuesday, May 12th. BNP Paribas Exane downgraded shares of DiaSorin from a “neutral” rating to an “underperform” rating in a report on Tuesday, July 7th. Deutsche Bank Aktiengesellschaft lowered shares of DiaSorin from a “hold” rating to a “sell” rating in a research report on Wednesday, June 17th. Finally, Piper Sandler initiated coverage on DiaSorin in a research report on Thursday, June 11th. They issued a “neutral” rating on the stock. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold”.
Get Our Latest Stock Report on DSRLF
DiaSorin Price Performance
About DiaSorin
DiaSorin S.p.A. is an Italy?based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over?the?counter (OTC) securities under the symbol DSRLF.
At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.
Read More
- Five stocks we like better than DiaSorin
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
- 3 Energy Stocks Racing to Fix AI’s Power Problem
- No Space For Panic: T-Mobile Shrugs Off The Starlink Threat
- Prepare for the Next Wave of Factory Automation With These 3 Standout Names
Receive News & Ratings for DiaSorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaSorin and related companies with MarketBeat.com's FREE daily email newsletter.
